Tough At The Top: Raj Denhoy On The Drive For Growth In A Maturing Medtech Industry
The medical technology industry was a solid if tricky bet for investors in 2017, and will be so in 2018. That is the view of Jefferies Healthcare US-based equity analyst Raj Denhoy. Speaking to In Vivo during the group's London meeting in fall 2017, he gave context to the motivations and drivers of medtechs large and small for 2018 and beyond.
You may also be interested in...
With the World Health Organization pressing for an inquiry into the coronavirus pandemic, it is clear that lessons must be learned for how future global public health emergencies must be handled. Medical technology has played a key role in halting the speed of the pandemic, but why has it taken an episode like COVID-19 for medtech’s true value to be recognized? ZS principal Brian Chapman says things must never go back to where they were.
Surveillance and track-and-trace have emerged as the new focus of the UK’s COVID-19 control strategy, but a workable plan is yet to crystalize.
Having rapidly built a large-capacity COVID-19 testing strategy, Germany’s health system leaders are developing the capabilities to avert future outbreaks.